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Background/aim: Systemic sclerosis (SSc) is a chronic systemic disease characterized by vascular damage, autoimmunity, and fibrosis
in the skin and internal organs. In this study, we tried to determine the causes of severe infection in patients with SSc and to reveal the
factors associated with severe infection.
Materials and methods: We retrospectively examined 214 SSc patients between January 2010 and August 2020. Forty-seven patients
with at least one severe infection and 167 patients without severe infection were compared.
Results: A total of 76 episodes of severe infections were detected in 47 (22%) patients. Common infections included pneumonia,
infected digital ulcer, urinary tract infections, and osteomyelitis. Female patients had a higher frequency in the group without severe
infection (91.6% vs. 80.9%, p = 0.035). Patients with severe infections had a higher frequency of digital ulcers (p < 0.001), cardiac (p
= 0.002), and GIS involvement (p < 0.001). In multivariable analysis, digital ulcer presence (OR: 2.849 [1.356–5.898] (p = 0.006) and
cardiac involvement (OR: 2.801 [1.248–6.285]) were associated with severe infection. Of the patients with severe infections, 34% had
recurrent severe infections. There was no difference in demographic and clinical characteristics between patients with recurrent and
nonrecurrent severe infections.
Conclusion: The presence of digital ulcer and cardiac involvement seem to be associated with a severe infection in patients with systemic
sclerosis. In patients with cardiac involvement and digital ulcers, more careful attention may be required for the development of severe
infections.
Key words: Severe infection, systemic sclerosis, digital ulcer, cardiac involvement

1. Introduction
Systemic sclerosis (SSc) is a chronic systemic disease
characterized by vascular damage, autoimmunity, and
fibrosis in the skin and internal organs. In SSc patients, a
wide spectrum of clinical manifestations could be seen,
from limited skin involvement and Raynaud’s phenomenon
to life-threatening organ involvement [1]. Infections are
an important cause of hospitalizations, morbidity, and
mortality in patients with SSc [2–4]. In SSc, infections
can be seen with an incidence rate of 20.3 per 100 person
years, of which more than half are serious infections [4].
In addition, the involvement of vital internal organs and
the use of strong immunosuppressive therapies increase
the frequency of infections [5]. Female gender, Raynaud’s
phenomenon, and especially esophageal dysmotility can
be considered among the important risk factors for the
prediction of infections [4].

In this study, we tried to determine the causes of severe
infection in patients with SSc and to reveal the factors
associated with severe infection.
2. Materials and methods
2.1. Patient selection
We retrospectively examined 214 patients with SSc
over the age of 18 years who applied to Department of
Rheumatology between January 2010 and August 2020
and who met the 2013 ACR/EULAR systemic sclerosis
classification criteria [6]. Severe infection was defined
as a condition that required intravenous antibiotic usage
or hospitalization or resulted in death, according to
previous studies [7–10]. The diagnosis of infection was
made by internal medicine specialists or infectious disease
specialists, or rheumatologists. The type of infection was
determined after anamnesis, physical examination, and
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laboratory tests. In this study, 47 patients with at least
one severe infection and 167 patients without a history of
severe infection were compared.
2.2. Definition of demographic and clinical features
The age of disease onset was accepted as the time of onset
of the first non–Raynaud’s disease manifestation. The
duration of the disease was accepted as the time between
the date of the first severe infection and the onset of the
disease in the severe infection group, whereas the time
between the date of the last visit and the onset of the
disease in the noninfection group. The duration of the
follow-up was defined as the time between the dates of the
last and first visits.
The patients were classified into diffuse cutaneous
SSc (dcSSc), limited cutaneous SSc (lcSSc) based on the
extent of skin involvement [11] and sine-scleroderma
(with no skin thickening on physical examination).
Diagnosis of interstitial lung disease (ILD) was established
by the presence of at least one of the classical pulmonary
manifestations, such as subpleural opacity, interstitial
reticular pattern, and honeycomb appearance on chest
computed tomography (Chest CT) [12]. Pulmonary
arterial hypertension (PAH) in right heart catheterization
was defined as a mean pulmonary pressure of 25 mmHg
and above and a pulmonary capillary wedge pressure of 15
mmHg or less [13]. The presence of cardiac involvement
was determined by the detection of arrhythmia, pericardial
effusion, pericardial thickening, or valvular heart disease,
which could not be explained by any other etiological
reasons, on electrocardiography or echocardiography
[14]. The presence of gastrointestinal system (GIS)
involvement was determined by signs indicating
impaired motility on manometric tests or endoscopic
interventions, or by enlarged esophagus in chest CT. The
presence of multi-organ/system involvement was defined
as patients in which two or more systems or organs
were affected. Immunosuppressive treatments and their
doses (treatments and doses until the onset of infection
in patients with severe infection) used during the entire
follow-up period were recorded. In the severe infection
group, the types of infections and the number of infection
episodes were recorded.
The
demographic,
clinical
and
laboratory
characteristics of SSc patients with and without severe
infection were compared. The study was reviewed and
approved by Clinical Research Ethics Committee (No: İ8541-20 Date: 09.28.2020) and conducted in accordance
with the ethical standards of the Helsinki Declaration.
2.3. Statistical analysis
The data were evaluated using the software IBM SPSS version
21 (Chicago, USA). Quantitative data were expressed as
median and interquartile range (IQR). Fisher’s exact test or
Chi-square test, whichever is appropriate, was used for the
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comparison of categorical data and Mann Whitney U test
was used to compare continuous data between groups with
and without severe infection. Multivariable analysis was
performed by logistic regression analysis, which modeled
independent predictors to predict severe infections, by
using possible factors identified in univariate analyses.
(Variables with a p-value < 0.1 on univariate analysis were
subsequently entered into the final multivariable model).
Hosmer-Lemeshow test was used to assess goodness-offit. In the analyses, p value under 0.05 was accepted as
statistically significant.
3. Results
A total of 76 episodes of severe infections were detected
in 47 (22%) patients. Common infections included
pneumonia, infected digital ulcer, urinary tract infections,
and osteomyelitis. The cumulative severe infection types
are presented in Table 1.
Patients with and without severe infection were
similar in terms of age (p = 0.744), duration of disease (p
= 0.138), and follow-up time (p = 0.118). Female patients
had a higher frequency in the group without severe
infection (91.6% vs. 80.9%, p = 0.035). Patients with severe
infections had a higher frequency of digital ulcers (p <
0.001), cardiac (p = 0.002), GIS involvement (p < 0.001)
and multiple organ/system involvement (p < 0.001). The
patients with dcSSc were more common in the group with
severe infection, but there was no statistical significance
(p = 0.051) (Table 2). There was no difference between the
groups with and without severe infection in the frequency
and doses of immunosuppressive therapy, except for
cyclophosphamide. Patients with severe infections had a
higher rate of cyclophosphamide use (p = 0.018), but with
the absence of statistically significant difference in the
cumulative doses between two groups (p = 0.195) (Table
2).
Univariate and multivariable logistic regression
analysis are presented in Table 3. In multivariable analysis,
digital ulcer presence (OR: 2.849 [1.356–5.898] (p = 0.006)
and cardiac involvement (OR: 2.801 [1.248–6.285]) were
associated with severe infection (Table 3).
Of the patients with severe infections, 34% (16/47)
had recurrent severe infections. There was no difference
in demographic, clinical, and therapeutic characteristics
between patients with recurrent and nonrecurrent severe
infections (Table 4).
Considering the frequency of severe infections based
on the involvement of major organs/systems, patients
with digital ulcer and cardiac involvement had the
highest frequency of skin and soft tissue infections, and
patients with interstitial lung disease, pulmonary arterial
hypertension, and GIS involvement had the highest
frequency of pneumonia (Table 5).
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Table 1. Causes of severe infections.
Cumulative infections*
Skin and soft tissue infections

30 (39.5)

Infected digital ulcer

16 (21)

Osteomyelitis

12 (15.8)

Infected pressure ulcers

2 (2.6)

Pneumonitis

22 (28.9)

Urinary tract infections

15 (19.7)

Gastrointestinal infections

4 (5.3)

Others

5 (6.6)
Ear, nose, and throat infections

3 (3.9)

Bacterial spondylodiscitis

1 (1.3)

Renal tuberculosis

1 (1.3)

Total

76

*Number and percent

A total of 11 patients had died during the follow-up
period. There was a higher mortality rate in the severe
infection group (9 (%19.1) vs. 2 (%1.2), p < 0.001). In
addition, the causes of death were respiratory failure
secondary to ILD in 3 patients, cardiovascular event in
2 patients, malignancy (B-cell lymphoma and gastric
carcinoma) in 2 patients, sepsis secondary to osteomyelitis
in 1 patient, and PAH-related respiratory failure in 1
patient in severe infection group. In the group without
severe infection, the causes of deaths were PAH-related
respiratory failure in 2 patients.
4. Discussion
It is known that there is an increased frequency of infections
in connective tissue diseases due to the disease itself and
immunosuppressive treatments [15]. However, there are a
limited number of studies of this subject on patients with
systemic sclerosis, which have shown that infections can
be frequently observed [3,4,15]. In this study, we tried to
show the causes of severe infection in patients with SSc
and possible related clinic factors.
In systemic sclerosis, infections can have major
effects on the frequency and duration of hospitalization
and mortality rates [16,17]. Therefore, determining the
factors that predict the development of infections may be
important for clinicians to follow up their patients. Previous
studies have indicated that Raynaud’s phenomenon, digital
ulcer, ILD, and GIS involvement are among the predictors
of infections in SSc patients [15]. Our study showed a
relationship between severe infections and male gender,
digital ulcer, GIS and cardiac involvement and use of

cyclophosphamide in univariate analyzes, and digital
ulcer presence and cardiac involvement in multivariable
analyses (Table 3).
There is a limited number of studies investigating the
causes of severe infections in SSc. A recent study reported
that pneumonia had the highest frequency (45%) in SSc
patients, followed by sepsis (32%), skin and soft tissue
infections (19%), and urinary tract infections (3%) [3].
Another study conducted in Taiwan reported that skin
and soft tissue infections were the most common causes,
followed by GIS infections, urinary tract infections, and
pneumonia [4]. In the present study, the most common
infections included skin and soft tissue infections,
particularly digital ulcer infection and osteomyelitis,
pneumonia, and urinary tract infections, consistent with
previous studies (Table 1). Our study also examined the
effects of SSc involvement in organs/systems on types of
infections (Table 5). Skin and soft tissue infections were
more common in patients with digital ulcer and cardiac
involvement, whereas pneumonia was higher in patients
with ILD, PAH and GIS involvement. A higher frequency
of infected digital ulcer and osteomyelitis can be expected
in those with digital ulcers. Microvascular damage is
known to occur in SSc [18]. In addition, the increase
in the frequency of digital ulcers and osteomyelitis in
patients with cardiac involvement suggests that circulatory
deterioration due to both microvascular and macrovascular
reasons may have set the ground for infections as a result
of delayed tissue healing. Therefore, we may have found a
relationship between severe infections and digital ulcer and
cardiac involvement in multivariable analyses (Table 3).
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Table 2. Comparison of patients with and without severe infection in terms of demographic and clinical features.
Severe infection group
N = 47

No infections
N = 167

p

Age, years*

52.1 [21.6]

53 [20.7]

0.744

Gender, female†

38 (80.9)

153 (91.6)

0.035

Age of disease onset, year*

42.2 [20.5]

45.6 [18.4]

0.128

Disease duration, year*

8,5 [13.75]

6.6 [9.7]

0.138

Follow-up time, year*

5.5 [5.5]

4.25 [5]

0.118

Raynaud phenomenon

45 (95.7)

158 (94.6)

1

Digital ulcer

29 (61.7)

49 (29.3)

<0.001

Interstitial lung disease

26 (55.3)

73 (43.7)

0.159

Pulmonary arterial hypertension

5 (10.6)

7 (4.2)

0.143

Cardiac involvement

18 (38.3)

29 (17.5)

0.002

Gastrointestinal involvement

23 (48.9)

38 (22.9)

<0.001

Arthritis/arthralgia

9 (19.1)

24 (14.5)

0.433

Multiple organ/system involvement

33 (70.2)

56 (33.5)

<0.001

dcSSc

17 (36.2)

37 (22.2)

0.051

lcSSc

30 (63.8)

125 (74.9)

0.135

Sine-scleroderma

0

5 (3)

0.588

Usage, ever

22 (46.8)

57 (34.1)

0.112

Usage, current

18 (38.3)

46 (27.5)

0.155

Total dose, mg*

4100 [4537.5]

6300 [10,975]

0.281

Usage, ever

7 (14.9)

24 (14.4)

0.928

Usage, current

4 (8.5)

18 (10.8)

0.790

Total dose, g*

129 [588]

85.5 [108.4]

0.304

Usage, ever

5 (10.6)

17 (10.2)

1

Usage, current

5 (10.6)

15 (9)

0.777

Total dose, g*

630 [735]

1125 [1478.8]

0.275

Usage, ever

11 (23.4)

17 (10.2)

0.018

Usage, current

2 (4.3)

1 (0.6)

0.122

Total dose, g*

9 [6]

6 [4.45]

0.195

Usage, ever

0

7 (4.2)

0.352

Usage, current

0

4 (2.4)

0.578

Total dose, g*

-

2 [13]

-

Clinical features†

Classification†

Immunosuppressive treatments
Glucocorticoids†

Azathioprine†

Mycophenolate mofetil†

Cyclophosphamide†

Rituximab†

dcSSc; diffuse cutaneous systemic sclerosis, g; gram, lcSSc; limited cutaneous systemic sclerosis, mg; milligram.
*Data are presented as median and IQR.
†Data are presented as numbers and percent.
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Similarly, it has been suggested that conditions associated
with pulmonary fibrosis, such as ILD, may pose a risk for
the development of infection associated with lung tissue
damage. It is also known that the frequency of aspiration
pneumonia increases in patients with SSc due to lower
esophageal sphincter dysfunction [15]. Therefore, we
expected an increased frequency of pneumonia in patients
with ILD or GIS involvement. Moreover, our data showed
an association between GIS involvement and the presence
of severe infection in univariate analysis, in line with
previous studies [4,15,19,20]. However, this relationship
did not reach statistical significance in multivariable
analyses. In SSc, GIS involvement causes aspiration
pneumonia as well as excessive bacterial proliferation,
ileus and malabsorption due to hypomotility which is
a result of intestinal fibrosis, thus setting the ground for
infections [21,22].
In our study, although male gender was found to be
a risk factor for the development of severe infections in
univariate analyses, no significant result was obtained in
multivariable analyses. The higher frequency of digital
ulcers in our male patients may have caused this result.
As far as we know, there is only one study examining the
effect of gender on the development of infections in SSc.
Although that study reported a 2.3–fold increase in the
risk of developing infections in women, it also reported
the absence of any effect of sex on major infections [4].
We believe that more comprehensive studies are needed to
evaluate the effect of gender on infections.

The use of immunosuppressants may be a risk factor
for the development of infections in autoimmune diseases
[15]. The use of glucocorticoids has been shown to be
a risk factor for the development of severe infections,
particularly in a dose dependent manner [15,23,24]. In
SSc, glucocorticoids are generally used at lower doses due
to the risk of triggering renal crises. In our center, the
daily dose generally does not exceed the equivalent of 7.5
mg of prednisolone. The lack of increased risk of serious
infections in glucocorticoid users can be attributed to
this dose restriction. Furthermore, cyclophosphamide
is an important therapeutic agent, especially in SSc
patients with severe organ involvement. After the use
of cyclophosphamide, the risk of severe infections
has been found to be increased in other autoimmune
diseases [15,25]. We also found a higher frequency of
cyclophosphamide use in patients with severe infections,
but in multivariable analysis it could not be shown to be
associated with severe infections. Moreover, we found a
lack of a total dose-dependent effect of cyclophosphamide
on infections. We also did not detect an opportunistic
infection in our patients that may occur due to the
immunosuppressive effect of cyclophosphamide.
This study has several limitations, such as having a
single-center retrospective study design and absence of
disease activity and severity assessments of the patients. We
could not evaluate all the potential confounding factors for
infection risk such as tobacco and alcohol use, vaccination
practice, surgery, pet ownership, hospitalization due to

Table 3. Associated factors for severe infection.
Univariate analysis

Multivariable analysis*

OR (95% CI)

p

OR (95% CI)

P

Age, year

1.006 [0.983–1.029]

0.613

-

-

Gender, male

2.588 [1.042–6.428]

0.040

2.280 [0.791–6.574]

0.127

Disease duration, year

1.040 [0.999–1.082]

0.057

1.005 [0.958–1.005]

0.838

Digital ulcer presence

3.880 [1.974–7.627]

<0.001

2.849 [1.356–5.898]

0.006

Interstitial lung disease

1.594 [0.831–3.058]

0.160

-

-

Pulmonary arterial hypertension

2.704 [0.817–8.951]

0.103

-

-

Cardiac involvement

2.932 [1.439–5.974]

0.003

2.801 [1.248–6.285]

0.013

Gastrointestinal involvement

3.228 [1.640–6.352]

0.001

2.098 [0.967–4.550]

0.061

dcSSc

1.991 [0.991–4.002]

0.053

0.789 [0.331–1.897]

0.592

Glucocorticoid usage, ever

1.698 [0.881–3.273]

0.144

-

-

Cyclophosphamide usage, ever

2.696 [1.163–6.252]

0.021

2.134 [0.775–5.880]

0.143

CI; Confidence interval, dcSSc; diffuse cutaneous systemic sclerosis, OR; Odds ratio,
*For multivariable model; Hosmer and lemeshow test chi-square 2.468, p = 0.963.
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Table 4. Comparison of patients with and without recurrent severe infection in terms of demographic, and clinical features.
Recurrent severe infection group Single severe infection group
N = 16
N = 31

P

Age, years*

59 [25.2]

49.75 [22.1]

0.119

Gender, female†

15 (93.8)

23 (74.2)

0.138

Age of disease onset, year*

44 [25.3]

36.5 [22.4]

0.307

Disease duration, year*

8.2 [12.3]

8.8 [15.7]

0.694

Follow-up time, year*

7 [8.1]

5 [4.7]

0.138

Raynaud phenomenon

15 (93.8)

30 (96.8)

1

Digital ulcer

11 (68.8)

18 (58.1)

0.475

Interstitial lung disease

10 (62.5)

16 (51.6)

0.477

Pulmonary arterial hypertension

1 (6.3)

4 (12.9)

0.648

Cardiac involvement

7 (43.8)

11 (35.5)

0.581

Gastrointestinal involvement

8 (50)

15 (48.4)

0.917

Arthritis/arthralgia

5 (31.3)

4 (12.9)

0.239

Multiple organ/system involvement

12 (75)

21 (67.7)

0.742

dcSSc

3 (18.8)

14 (45.2)

0.074

lcSSc

13 (81.3)

17 (54.8)

0.074

Sine-scleroderma

0

0

-

Usage, ever

8 (50)

14 (45.2)

0.753

Usage, current

6 (37.5)

12 (38.7)

0.936

Total dose, mg*

4100 [2250]

4081 [8487.5]

0.971

Usage, ever

2 (12.5)

5 (16.1)

1

Usage, current

1 (6.3)

3 (9.7)

1

Total dose, g*

135 [–]

129 [711.5]

1

Usage, ever

0

5 (16.1)

0.150

Usage, current

0

5 (16.1)

0.150

Total dose, g*

-

630 [735]

-

Usage, ever

4 (25)

7 (22.6)

1

Usage, current

1 (6.3)

1 (3.2)

1

Total dose, g*

9 [51.75]

6.75 [6]

0.788

Clinical features†

Classification†

Immunosuppressive treatments
Glucocorticoids†

Azathioprine†

Mycophenolate mofetil†

Cyclophosphamide†

dcSSc; diffuse cutaneous systemic sclerosis, g; gram, lcSSc; limited cutaneous systemic sclerosis, mg; milligram.
*Data are presented as median and IQR.
†Data are presented as numbers and percent.
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Table 5. Severe infection event frequencies according to organ involvement.

Digital
ulcer

Pulmonary
Interstitial lung
arterial
disease
hypertension

Gastrointestinal
involvement

Cardiac
involvement

Multiple
organ/system
involvement

Skin and soft tissue infections*

27 (52.9)

9 (20.4)

1 (12.5)

14 (35)

14 (41.2)

23 (41.1)

Pneumonitis*

15 (29.4)

19 (43.2)

4 (50)

16 (40)

13 (38.2)

19 (33.9)

Urinary tract infections*

7 (13.7)

10 (22.7)

2 (25)

4 (10)

6 (17.6)

8 (14.3)

Gastrointestinal infections*

0

3 (6.8)

1 (12.5)

3 (7.5)

0

3 (5.4)

Others*

2 (3.9)

3 (6.8)

0

3 (7.5)

1 (2.9)

3 (5.4)

Total

51

44

8

40

34

56

*Event number and percent.

noninfection reasons and comorbidities. Since our current
study has a single-center retrospective study design, we
may have been insufficient to obtain the data of patients
who presented to another health center with severe
infections. In addition, it has the strengths of being one of
the few studies examining factors associated with severe
infections in SSc patients.
In conclusion, the presence of digital ulcer and cardiac
involvement seem to be associated with severe infection
in patients with systemic sclerosis. In patients with cardiac
involvement and digital ulcers, more careful attention
may be required for the development of severe infections.
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